Box

	DOCKE	Γ NO. : I	SIS-4823
₹=		IN THE	UNITE

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Weinbach, et al.

Serial No.: Not yet assigned

Group Art Unit: Not yet assigned

Filing Date: Herewith

Examiner: Not yet assigned

or: Pulsatile Release Compositions And Methods For Enhanced Intestinal Drug

Absorption

Patent Application

EXPRESS MAIL LABEL NO: EL568027040US DATE OF DEPOSIT: August 22, 2001

	☐ Provisional ☐ Design	DECEIVED		
	ant Commissioner for Patents ington DC 20231	AUG 22 2001		
Sir:		And the state of t		
,	PATENT APPLICATION TRANSMITT	AL LETTER		
	Transmitted herewith for filing, please find			
\boxtimes				
	It is a continuing application, as follows:			
	☐ continuation ☐ divisional ☐ continuation-in-	part of prior application number		
	A Provisional Patent Application under 37 C.F.R. 1.53	3(c).		
	A Design Patent Application (submitted in duplicate).			
	Request for Nonpublication. The invention(s) disclo	sed in the present application		

filed herewith has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing. Thus, pursuant to 35 U.S.C. §122(b)(2)(B)(i), Applicant(s) request that the above-identified patent application not be published.

Includ	ing the	followin	ng:	
	Provisional Application Cover Sheet.			
\boxtimes	New or Revised Specification, including pages 1 to 59 containing:			
	\boxtimes	Specif	ication	
	\boxtimes	Claims	s ·	
	⊠ Abstract			
☐ Substitut			tute Specification, including Claims and Abstract.	
			The present application is a continuation application of Application No filed The present application includes the Specification of the parent application which has been revised in accordance with the amendments filed in the parent application. Since none of those amendments incorporate new matter into the parent application, the present revised Specification also does not include new matter.	
			The present application is a continuation application of Application No filed, which in turn is a continuation-in-part of Application No filed The present application includes the Specification of the parent application which has been revised in accordance with the amendments filed in the parent application. Although the amendments in the parent C-I-P application may have incorporated new matter, since those are the only revisions included in the present application, the present application includes no new matter in relation to the parent application.	
	A copy of earlier application Serial No			
	Please enter the following amendment to the Specification under the Cross-Reference to Related Applications section (or create such a section): "This Application:			

DOC	KET NO.: ISIS-4823 - 3 - Application Serial Nofiled	PATEN			
	Signed Statement attached deleting inventor(s) named in the prior	application.			
	A Preliminary Amendment.				
\boxtimes	3 Sheets of Formal Drawings.				
	☐ Drawing view to publish: Figure				
	Petition to Accept Photographic Drawings.				
	☐ Petition Fee				
	An Executed Unexecuted Declaration or Oath and Power of	of Attorney.			
	An Associate Power of Attorney.				
	An Executed Copy of Executed Assignment of the Invention to				
	☐ A Recordation Form Cover Sheet. ☐ Recordation Fee - \$40.00.	•			
	The prior application is assigned of record to				
	Priority is claimed under 35 U.S.C. § 119 of Patent Application				
	filed in (A Certified Copy of each of the above applications for whe claimed: is enclosed. has been filed in prior application Serial No	nich priority is			
	Please enter the following amendment to the first sentence (or create such a sentence): "This application claims beneapplication No, which was published under in English."	fit of international			

Applicant(s) by its/their undersigned attorney, claims small entity status under 37

DOCKET NO.: ISIS-4823 C.F.R. §1.27 as: an Independent Inventor a Small Business Concern ☐ a Nonprofit Organization. \boxtimes Diskette Containing DNA/Amino Acid Sequence Information. \boxtimes Statement to Support Submission of DNA/Amino Acid Sequence Information. \boxtimes Sequence listing consisting of pages <u>3</u>. The computer readable form in this application _____, is identical with that filed in П Application Serial Number ______, filed ______. In accordance with 37 CFR 1.821(e), please use the \square first-filed, \square last-filed or \square only computer readable form filed in that application as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant application. A paper copy of the Sequence Listing is included in the originally-filed specification of the instant application, included in a separately filed preliminary amendment for incorporation into the specification. Information Disclosure Statement. Attached Form 1449. Copies of each of the references listed on the attached Form PTO-1449 are П enclosed herewith. A copy of Petition for Extension of Time as filed in the prior case.

 \boxtimes Return Receipt Postcard (should be specifically itemized).

Appended Material as follows: _

1.20(d).

DOC	KET NO	.: ISIS-4823		- 5 -			PATENT
	Other a	Other as follows:					
							-
FEE (CALCUL	ATION:					
	calculat	in this applica ting the filing ag purposes.)	_				plication before ast be retained
8888	*****	********	3333333	SMAL	L ENTITY	NOT SM	IALL ENTITY
				RATE	FEE	RATE	FEE
PROV	ISIONAL A	PPLICATION		\$75.00	\$	\$150.00	\$
DESIG	GN APPLICA	ATION		\$160.00	\$	\$320.00	\$
UTILI	TY APPLIC	ATIONS BASE FI	EE	\$355.00	\$	\$710.00	\$710.00
CALC		ATION; ALL CLA FTER ENTRY OF					
		No. Filed	No. Extra	<u> </u>	*******	*********	***********
	TOTAL CLAIMS	20 - 20 =	0	\$9 each	\$	\$18 each	\$0
	NDEP. CLAIMS	2 - 3 =	0	\$40 each	\$	\$80 each	\$0
	FIRST PRESI DEPENDENT	ENTATION OF M	ULTIPLE	\$135	\$	\$270	\$
ADD	ITIONAL FI	LING FEE			\$	_8333333	8 s
TOTA	AL FILING F	EE DUE		<u> </u>	\$		\$710.00
	A Che	ck is enclosed	in the am	ount of \$	•		
\boxtimes	The Co	ommissioner is	s authorize	ed to charge	payment of	the following	fees and to
		any overpaym application to					g the pendency I in duplicate.
		The foregoing amount due.					
	\boxtimes	•	_	_	including fe	ees for the pres	sentation of extra
claims under 37 C.F.F Any additional patent					processing fe	es under 37 C	.F.R. 1.17 or

The Commissioner is hereby requested to grant an extension of time for the appropriate length of time, should one be necessary, in connection with this filing or any future filing submitted to the U.S. Patent and Trademark Office in the above-identified application during the pendency of this application. The Commissioner is further authorized to charge any fees related to any such extension of time to deposit account 23-3050. This sheet is provided in duplicate.

SHOULD ANY DEFICIENCIES APPEAR with respect to this application, including deficiencies in payment of fees, missing parts of the application or otherwise, the United States Patent and Trademark Office is respectfully requested to promptly notify the undersigned.

Date: August 22,2001

Emma Dailey

Registration No. P-48,491

Woodcock Washburn Kurtz Mackiewicz & Norris LLP One Liberty Place - 46th Floor Philadelphia PA 19103 Telephone: (215) 568-3100

Facsimile: (215) 568-3439

©2000 WWKMN

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re	Application of:			
Weinb	bach, et al.			
Serial	l No.:	Group Art Unit:		
Filing	g Date:	Examiner:		
For:	Pulsatile Release Compositions And Mo Absorption	ethods For Enhanced Intestinal Drug		
Assista	SEQUENCE ant Commissioner for Patents ngton DC 20231			
		EXPRESS MAIL LABEL NO.: EL568027040US DATE OF DEPOSIT: AUGUST 22, 2001		
ST	ATEMENT TO SUPPORT FILING A WITH 37 CFR §§ 1.82	ND SUBMISSION IN ACCORDANCE 11 THROUGH 1.825		
	•	requirements of 37 C.F.R. §1.821(f), that the able copies of the Sequence Listing, submitted and (e), respectively are the same.		
\boxtimes	I hereby state that the submission filed in accordance with 37 CFR §1.821(g) does not include new matter.			
	ř	in accordance with 37 CFR §1.821(h) does not closure in the international application as filed.		
	included in the substitute sheet(s) of	made in accordance with 37 CFR §1.825(a), if the Sequence Listing are supported in the I hereby state that the substitute sheet(s) of the new matter.		
	I hereby state that the substitute copy	of the computer readable form, submitted in		

accordance with 37 CFR $\S 1.825(b),$ is the same as the amended Sequence Listing.

DOCK	KET NO.: ISIS-4823	- 2 -	PATENT
	I hereby state that the substaccordance with 37 CFR §1.		ter readable form, submitted in data to that originally filed.
Date:	August 22, 2001	Emma R. Dail	Dey Cuy

Registration No. P48,491

Woodcock Washburn Kurtz Mackiewicz & Norris LLP One Liberty Place - 46th Floor Philadelphia PA 19103 Telephone: (215) 568-3100 Facsimile: (215) 568-3439

© 1997 WWKMN